title: Long-Term Follow-Up of Patients after Percutaneous Coronary Intervention with Everolimus-Eluting Bioresorbable Vascular Scaffold.
abstract: Bioresorbable vascular scaffolds (BVS) were developed to improve the long-term results of percutaneous coronary intervention, restoring vasomotion.
  To report very late follow-up of everolimus-eluting Absorb BVS (Abbott Vascular, Santa Clara, USA) in our center.
  Observational retrospective study, in a single Brazilian center, from August 2011 to October 2013, including 49 patients submitted to Absorb BVS implantation. Safety and efficacy outcomes were analyzed in the in-hospital and very late follow-up phases (> 2 years).
  All 49 patients underwent a minimum follow-up of 2.5 years and a maximum of 4.6 years. Mean age was 56.8 ± 7.6 years, 71.4% of the patients were men, and 26.5% were diabetic. Regarding clinical presentation, the majority (94%) had stable angina or silent ischemia. Device success was achieved in 100% of cases with 96% overall procedure success rate. Major adverse cardiovascular events rate was 4% at 30 days, 8.2% at 1 year, and 12.2% at 2 years, and there were no more events until 4.6 years. There were 2 cases of thrombosis (1 subacute and 1 late).
  In this preliminary analysis, Absorb BVS showed to be a safe and effective device in the very late follow-up. Establishing the efficacy and safety profiles of these devices in more complex scenarios is necessary.
  Os suportes vasculares bioabsorvíveis (SVB) foram desenvolvidos com o intuito de melhorar os resultados da intervenção coronária percutânea a longo prazo, restabelecendo-se a vasomotricidade.
  Reportar o seguimento muito tardio do implante do SVB eluidor de everolimus Absorb® (Abbot Vascular, Santa Clara, EUA) em nosso centro.
  Estudo observacional, retrospectivo, em um único centro brasileiro, que incluiu 49 pacientes submetidos ao implante do SVB Absorb® entre agosto/2011 e outubro/2013. Foram analisados os desfechos de segurança e eficácia na fase hospitalar e bastante tardia (> 2 anos).
  Todos os 49 pacientes completaram um seguimento mínimo de 2,5 anos, sendo o máximo de 4,6 anos. A média de idade foi 56,8 ± 7,6 anos, sendo 71,4% da população estudada do sexo masculino e 26,5% composta por diabéticos. Considerando a apresentação clínica, a grande maioria (94%) tinha angina estável ou isquemia silenciosa. Obteve-se sucesso do dispositivo em 100% dos casos e do procedimento, em 96%. A taxa de eventos cardiovasculares maiores foi de 4% aos 30 dias, de 8,2% em 1 ano, e de 12,2% em 2 anos, sem mais eventos até 4,6 anos. Houve 2 casos de trombose (1 subaguda e 1 tardia) até o último seguimento.
  Nesta análise preliminar, o uso do SVB Absorb® mostrou-se seguro e eficaz no seguimento bastante tardio. Faz-se necessário estabelecer o perfil de eficácia e segurança destes dispositivos em cenários de maior complexidade.
authors.affiliation: Instituto Dante Pazzanese de Cardiologia, São Paulo, SP - Brazil.
authors.forename: Rafael Alexandre
authors.initials: RA
authors.lastname: Meneguz-Moreno
authors.affiliation: Instituto Dante Pazzanese de Cardiologia, São Paulo, SP - Brazil.
authors.forename: José de Ribamar
authors.initials: JR
authors.lastname: Costa
authors.affiliation: Instituto Dante Pazzanese de Cardiologia, São Paulo, SP - Brazil.
authors.forename: Freddy Antônio Britto
authors.initials: FA
authors.lastname: Moscoso
authors.affiliation: Instituto Dante Pazzanese de Cardiologia, São Paulo, SP - Brazil.
authors.forename: Rodolfo
authors.initials: R
authors.lastname: Staico
authors.affiliation: Instituto Dante Pazzanese de Cardiologia, São Paulo, SP - Brazil.
authors.forename: Luiz Fernando Leite
authors.initials: LF
authors.lastname: Tanajura
authors.affiliation: Instituto Dante Pazzanese de Cardiologia, São Paulo, SP - Brazil.
authors.forename: Marinella Patrizia
authors.initials: MP
authors.lastname: Centemero
authors.affiliation: Instituto Dante Pazzanese de Cardiologia, São Paulo, SP - Brazil.
authors.forename: Auréa Jacob
authors.initials: AJ
authors.lastname: Chaves
authors.affiliation: Instituto Dante Pazzanese de Cardiologia, São Paulo, SP - Brazil.
authors.forename: Andrea Claudia Leão de Sousa
authors.initials: AC
authors.lastname: Abizaid
authors.affiliation: Instituto Dante Pazzanese de Cardiologia, São Paulo, SP - Brazil.
authors.forename: Amanda Guerra de Moraes Rego E
authors.initials: AG
authors.lastname: Sousa
authors.affiliation: Instituto Dante Pazzanese de Cardiologia, São Paulo, SP - Brazil.
authors.forename: Alexandre Antonio Cunha
authors.initials: AA
authors.lastname: Abizaid
mesh_terms: D020341:Absorbable Implants; D001938:Brazil; D017023:Coronary Angiography; D054855:Drug-Eluting Stents; D004867:Equipment Design; D000068338:Everolimus / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D017202:Myocardial Ischemia / Q000628:therapy; D062645:Percutaneous Coronary Intervention / Q000295:instrumentation* / Q000379:methods*; D011183:Postoperative Complications; D015203:Reproducibility of Results; D012189:Retrospective Studies; D013997:Time Factors; D054457:Tissue Scaffolds; D016896:Treatment Outcome
chemical_list: D000068338:Everolimus